Evidence map›Paper›PMID 36671438›Full record

ArticleBiomolecules2022

Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease.

Mulan Deng, Hongyu Zhou, Zhicheng Liang, Zhaoyang Li, Yanping Wang, Wanyi Guo, April Yuanyi Zhao, Fanghong Li, Yunping Mu, Allan Zijian Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mulan DengThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510000, China.
Hongyu ZhouThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510000, China.
Zhicheng LiangThe School of Medicine, South China University of Technology, Guangzhou 510000, China.
Zhaoyang LiThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510000, China.
Yanping WangThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510000, China.
Wanyi GuoThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510000, China.
April Yuanyi ZhaoThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510000, China.
Fanghong LiThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510000, China.
Yunping MuThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510000, China.
Allan Zijian ZhaoThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510000, China.
Guangdong University of Technology · CNSouth China University of Technology · CN

Funding

The Guangdong Innovative Research Team Program 2016ZT06Y432The Key Research and Development Program of Guangdong Province 2019B020227003The Key Research and Development Program of Guangdong Province for "Innovative drug creation" 2019B020201015the National Key R&D Program of China 2018YFA0800603the National Natural Science Foundation of China 81630021the National Natural Science Foundation of China 82100064The Startup R&D Funding of Guangdong University of Technology 50010102
6 · The paper itself

Abstract

Fabry disease (FD) is a progressive multisystemic disease characterized by lysosomal enzyme deficiency. Enzyme replacement therapy (ERT) is one of the most significant advancements and breakthroughs in treating FD. However, limited resources and the high cost of ERT might prevent patients from receiving prompt and effective therapy, thereby resulting in severe complications. Future progress in ERT can uncover promising treatment options. In this study, we developed and validated a recombinant enzyme (Lanzyme) based on a CHO-S cell system to provide a new potential option for FD therapy. Our results indicated that Lanzyme was heavily glycosylated, and its highest activity was similar to a commercial enzyme (Fabrazyme

Indexed as

alpha-GalactosidaseEnzyme Replacement TherapyFabry DiseaseRecombinant ProteinsAnimalsMicealpha-GalactosidaseRecombinant Proteinsenzyme replacement therapy (ERT)Fabry disease (FD)globotriaosylceramide (Gb3)Lanzymelysosomal storage disorders (LSDs)recombinant human α-galactosidase A (rhα-Gal A)

Identifiers

PMID36671438
PMCPMC9855849
OpenAlexW4313414500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.